Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy

Exercise intolerance is a prominent symptom in patients with mitochondrial myopathy (MM), but it is still unsettled whether exercise training is safe and beneficial for patients with MM. To address this, we studied the effect of 12 weeks cycle training on exercise capacity, quality of life and under...

Full description

Saved in:
Bibliographic Details
Published inBrain (London, England : 1878) Vol. 129; no. 12; pp. 3402 - 3412
Main Authors Jeppesen, Tina D., Schwartz, Marianne, Olsen, David B., Wibrand, Flemming, Krag, Thomas, Dunø, Morten, Hauerslev, Simon, Vissing, John
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 01.12.2006
Oxford Publishing Limited (England)
Subjects
Online AccessGet full text
ISSN0006-8950
1460-2156
1460-2156
DOI10.1093/brain/awl149

Cover

Abstract Exercise intolerance is a prominent symptom in patients with mitochondrial myopathy (MM), but it is still unsettled whether exercise training is safe and beneficial for patients with MM. To address this, we studied the effect of 12 weeks cycle training on exercise capacity, quality of life and underlying molecular and cellular events in five patients with single large-scale deletions, one with a microdeletion and 14 with point mutations of mitochondrial DNA (mtDNA), and 13 healthy subjects. Each training session lasted 30 min, and was performed at an intensity of 70% of VO2max (maximal oxygen uptake). Each subject performed 50 training sessions in 12 weeks. All subjects were evaluated before and after training, and 13 MM patients were studied after 8 weeks of deconditioning. Evaluation included VO2max and mutation load and mtDNA quantity, mitochondrial enzymatic activity, and number of centrally nucleated, apoptotic, ragged red and cytochrome oxidase (COX)-negative fibres in muscle biopsies from the quadriceps muscle. After 12 weeks of training, VO2max and muscle citrate synthase increased in MM (26 and 67%) and healthy (17 and 65%) subjects, while mtDNA quantity in muscle only increased in the MM patients (81%). In the MM patients, training did not change mtDNA mutation load in muscle, mitochondrial enzyme complex activities, muscle morphology and plasma creatine kinase. After deconditioning, VO2max and citrate synthase activity returned to values before training, while muscle mtDNA mutation load decreased. These findings show that aerobic training efficiently improves oxidative capacity in MM patients. Based on unchanged levels of mutant load in muscle, morphological findings on muscle biopsy and plasma creatine kinase levels during training, the treatment appears to be safe. Regular, supervised aerobic exercise is therefore recommended in MM patients with the studied mutations.
AbstractList Exercise intolerance is a prominent symptom in patients with mitochondrial myopathy (MM), but it is still unsettled whether exercise training is safe and beneficial for patients with MM. To address this, we studied the effect of 12 weeks cycle training on exercise capacity, quality of life and underlying molecular and cellular events in five patients with single large-scale deletions, one with a microdeletion and 14 with point mutations of mitochondrial DNA (mtDNA), and 13 healthy subjects. Each training session lasted 30 min, and was performed at an intensity of 70% of VO2max (maximal oxygen uptake). Each subject performed 50 training sessions in 12 weeks. All subjects were evaluated before and after training, and 13 MM patients were studied after 8 weeks of deconditioning. Evaluation included VO2max and mutation load and mtDNA quantity, mitochondrial enzymatic activity, and number of centrally nucleated, apoptotic, ragged red and cytochrome oxidase (COX)-negative fibres in muscle biopsies from the quadriceps muscle. After 12 weeks of training, VO2max and muscle citrate synthase increased in MM (26 and 67%) and healthy (17 and 65%) subjects, while mtDNA quantity in muscle only increased in the MM patients (81%). In the MM patients, training did not change mtDNA mutation load in muscle, mitochondrial enzyme complex activities, muscle morphology and plasma creatine kinase. After deconditioning, VO2max and citrate synthase activity returned to values before training, while muscle mtDNA mutation load decreased. These findings show that aerobic training efficiently improves oxidative capacity in MM patients. Based on unchanged levels of mutant load in muscle, morphological findings on muscle biopsy and plasma creatine kinase levels during training, the treatment appears to be safe. Regular, supervised aerobic exercise is therefore recommended in MM patients with the studied mutations.
Exercise intolerance is a prominent symptom in patients with mitochondrial myopathy (MM), but it is still unsettled whether exercise training is safe and beneficial for patients with MM. To address this, we studied the effect of 12 weeks cycle training on exercise capacity, quality of life and underlying molecular and cellular events in five patients with single large-scale deletions, one with a microdeletion and 14 with point mutations of mitochondrial DNA (mtDNA), and 13 healthy subjects. Each training session lasted 30 min, and was performed at an intensity of 70% of VO2max (maximal oxygen uptake). Each subject performed 50 training sessions in 12 weeks. All subjects were evaluated before and after training, and 13 MM patients were studied after 8 weeks of deconditioning. Evaluation included VO2max and mutation load and mtDNA quantity, mitochondrial enzymatic activity, and number of centrally nucleated, apoptotic, ragged red and cytochrome oxidase (COX)-negative fibres in muscle biopsies from the quadriceps muscle. After 12 weeks of training, VO2max and muscle citrate synthase increased in MM (26 and 67%) and healthy (17 and 65%) subjects, while mtDNA quantity in muscle only increased in the MM patients (81%). In the MM patients, training did not change mtDNA mutation load in muscle, mitochondrial enzyme complex activities, muscle morphology and plasma creatine kinase. After deconditioning, VO2max and citrate synthase activity returned to values before training, while muscle mtDNA mutation load decreased. These findings show that aerobic training efficiently improves oxidative capacity in MM patients. Based on unchanged levels of mutant load in muscle, morphological findings on muscle biopsy and plasma creatine kinase levels during training, the treatment appears to be safe. Regular, supervised aerobic exercise is therefore recommended in MM patients with the studied mutations.Exercise intolerance is a prominent symptom in patients with mitochondrial myopathy (MM), but it is still unsettled whether exercise training is safe and beneficial for patients with MM. To address this, we studied the effect of 12 weeks cycle training on exercise capacity, quality of life and underlying molecular and cellular events in five patients with single large-scale deletions, one with a microdeletion and 14 with point mutations of mitochondrial DNA (mtDNA), and 13 healthy subjects. Each training session lasted 30 min, and was performed at an intensity of 70% of VO2max (maximal oxygen uptake). Each subject performed 50 training sessions in 12 weeks. All subjects were evaluated before and after training, and 13 MM patients were studied after 8 weeks of deconditioning. Evaluation included VO2max and mutation load and mtDNA quantity, mitochondrial enzymatic activity, and number of centrally nucleated, apoptotic, ragged red and cytochrome oxidase (COX)-negative fibres in muscle biopsies from the quadriceps muscle. After 12 weeks of training, VO2max and muscle citrate synthase increased in MM (26 and 67%) and healthy (17 and 65%) subjects, while mtDNA quantity in muscle only increased in the MM patients (81%). In the MM patients, training did not change mtDNA mutation load in muscle, mitochondrial enzyme complex activities, muscle morphology and plasma creatine kinase. After deconditioning, VO2max and citrate synthase activity returned to values before training, while muscle mtDNA mutation load decreased. These findings show that aerobic training efficiently improves oxidative capacity in MM patients. Based on unchanged levels of mutant load in muscle, morphological findings on muscle biopsy and plasma creatine kinase levels during training, the treatment appears to be safe. Regular, supervised aerobic exercise is therefore recommended in MM patients with the studied mutations.
Exercise intolerance is a prominent symptom in patients with mitochondrial myopathy (MM), but it is still unsettled whether exercise training is safe and beneficial for patients with MM. To address this, we studied the effect of 12 weeks cycle training on exercise capacity, quality of life and underlying molecular and cellular events in five patients with single large-scale deletions, one with a microdeletion and 14 with point mutations of mitochondrial DNA (mtDNA), and 13 healthy subjects. Each training session lasted 30 min, and was performed at an intensity of 70% of VO sub(2max) (maximal oxygen uptake). Each subject performed 50 training sessions in 12 weeks. All subjects were evaluated before and after training, and 13 MM patients were studied after 8 weeks of deconditioning. Evaluation included VO sub(2max) and mutation load and mtDNA quantity, mitochondrial enzymatic activity, and number of centrally nucleated, apoptotic, ragged red and cytochrome oxidase (COX)-negative fibres in muscle biopsies from the quadriceps muscle. After 12 weeks of training, VO sub(2max) and muscle citrate synthase increased in MM (26 and 67%) and healthy (17 and 65%) subjects, while mtDNA quantity in muscle only increased in the MM patients (81%). In the MM patients, training did not change mtDNA mutation load in muscle, mitochondrial enzyme complex activities, muscle morphology and plasma creatine kinase. After deconditioning, VO sub(2max) and citrate synthase activity returned to values before training, while muscle mtDNA mutation load decreased. These findings show that aerobic training efficiently improves oxidative capacity in MM patients. Based on unchanged levels of mutant load in muscle, morphological findings on muscle biopsy and plasma creatine kinase levels during training, the treatment appears to be safe. Regular, supervised aerobic exercise is therefore recommended in MM patients with the studied mutations.
Author Wibrand, Flemming
Olsen, David B.
Vissing, John
Schwartz, Marianne
Hauerslev, Simon
Krag, Thomas
Jeppesen, Tina D.
Dunø, Morten
Author_xml – sequence: 1
  givenname: Tina D.
  surname: Jeppesen
  fullname: Jeppesen, Tina D.
  organization: Department of Neurology, Neuromuscular Research Unit, The Copenhagen Muscle Research Centre Rigshospitalet, Copenhagen, Denmark
– sequence: 2
  givenname: Marianne
  surname: Schwartz
  fullname: Schwartz, Marianne
  organization: Department of Clinical Genetics, National University Hospital Rigshospitalet, Copenhagen, Denmark
– sequence: 3
  givenname: David B.
  surname: Olsen
  fullname: Olsen, David B.
  organization: Department of Neurology, Neuromuscular Research Unit, The Copenhagen Muscle Research Centre Rigshospitalet, Copenhagen, Denmark
– sequence: 4
  givenname: Flemming
  surname: Wibrand
  fullname: Wibrand, Flemming
  organization: Department of Clinical Genetics, National University Hospital Rigshospitalet, Copenhagen, Denmark
– sequence: 5
  givenname: Thomas
  surname: Krag
  fullname: Krag, Thomas
  organization: Department of Neurology, Neuromuscular Research Unit, The Copenhagen Muscle Research Centre Rigshospitalet, Copenhagen, Denmark
– sequence: 6
  givenname: Morten
  surname: Dunø
  fullname: Dunø, Morten
  organization: Department of Clinical Genetics, National University Hospital Rigshospitalet, Copenhagen, Denmark
– sequence: 7
  givenname: Simon
  surname: Hauerslev
  fullname: Hauerslev, Simon
  organization: Department of Neurology, Neuromuscular Research Unit, The Copenhagen Muscle Research Centre Rigshospitalet, Copenhagen, Denmark
– sequence: 8
  givenname: John
  surname: Vissing
  fullname: Vissing, John
  organization: Department of Neurology, Neuromuscular Research Unit, The Copenhagen Muscle Research Centre Rigshospitalet, Copenhagen, Denmark
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18360636$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/16815877$$D View this record in MEDLINE/PubMed
BookMark eNqF0stvEzEQB2ALFdG0cOOMLCTgwlJ7_T5WFVCkSBx4COVieZ1Z4rJrB3tDm_8ehwQqVQJOPvgbP-Y3J-gopggIPabkFSWGnXXZhXjmrgfKzT00o1ySpqVCHqEZIUQ22ghyjE5KuSKEctbKB-iYSk2FVmqG7Dnk1AWPp90xIX7FoeDiesAuLnEY1zn9gILhBrIPBbB3a-fDtMUh4rWbAsSp4OswrfAYpuRXKS5zcAMet6lur7YP0f3eDQUeHdZT9OnN648Xl838_dt3F-fzxnOupsZRTUF4UK2XnWiXoLk0SjLhhFfa9JR3hIMD1bMlYRyMlJpw6hhxppdA2Sl6sT-3Pvj7Bspkx1A8DIOLkDbFKkUV57rlVT7_p6ytMUoY_V9IDTdacFbh0zvwKm1yrN-tpgLSsh16ckCbboSlXecwury1v6Oo4NkBuOLd0GcXa8dvnWaSSCare7l3PqdSMvS3hNjdRNhfE2H3E1F5e4fX-GpwKe4SH_5W1OyLQpng5s8FLn-zUjEl7OWXheWLz4rP5cJ-YD8Bg0HKZA
CODEN BRAIAK
CitedBy_id crossref_primary_10_1007_s10540_007_9042_3
crossref_primary_10_1038_s41392_024_02044_3
crossref_primary_10_3390_ijms24098154
crossref_primary_10_1016_j_neurol_2009_07_006
crossref_primary_10_1016_S1474_4422_10_70116_2
crossref_primary_10_1177_0883073814538512
crossref_primary_10_1212_WNL_0000000000008861
crossref_primary_10_1371_journal_pone_0114462
crossref_primary_10_1134_S0006297913090034
crossref_primary_10_1212_01_wnl_0000341274_61236_02
crossref_primary_10_1007_s11659_012_0305_4
crossref_primary_10_1007_s00347_007_1643_5
crossref_primary_10_1590_1414_431x20143467
crossref_primary_10_1155_2015_945901
crossref_primary_10_1016_j_nurt_2008_07_002
crossref_primary_10_4254_wjh_v13_i11_1707
crossref_primary_10_1016_j_bbagen_2013_12_025
crossref_primary_10_1073_pnas_2200549119
crossref_primary_10_1097_WCO_0000000000000743
crossref_primary_10_1016_S0035_3787_07_92636_3
crossref_primary_10_1097_CND_0b013e3181a8d36b
crossref_primary_10_1007_s10545_015_9834_8
crossref_primary_10_3389_fphys_2024_1404657
crossref_primary_10_3390_antiox11030510
crossref_primary_10_1002_jpen_1826
crossref_primary_10_1016_j_nmd_2012_08_005
crossref_primary_10_1055_a_2264_2067
crossref_primary_10_3109_07853890_2011_605389
crossref_primary_10_1016_j_ymgme_2009_11_005
crossref_primary_10_1007_s10545_010_9085_7
crossref_primary_10_1007_s11940_009_0046_0
crossref_primary_10_1007_s10863_014_9559_7
crossref_primary_10_1002_14651858_CD004426_pub3
crossref_primary_10_1186_s12967_023_04626_1
crossref_primary_10_1097_PEP_0000000000000016
crossref_primary_10_1111_1753_0407_12561
crossref_primary_10_1111_j_1475_097X_2012_01122_x
crossref_primary_10_3109_07420520903553443
crossref_primary_10_1016_S0162_0908_08_79159_1
crossref_primary_10_1016_j_nut_2019_06_025
crossref_primary_10_1038_nrneurol_2013_129
crossref_primary_10_1146_annurev_pathol_4_110807_092314
crossref_primary_10_1007_s13311_012_0175_0
crossref_primary_10_3390_pharmaceutics12111083
crossref_primary_10_1016_j_mito_2025_102010
crossref_primary_10_1249_JES_0000000000000250
crossref_primary_10_1371_journal_pone_0219628
crossref_primary_10_1186_s12891_017_1781_0
crossref_primary_10_1371_journal_pone_0064067
crossref_primary_10_3390_jcm9103113
crossref_primary_10_31362_patd_570009
crossref_primary_10_1186_ar4076
crossref_primary_10_1016_j_ymgme_2021_12_010
crossref_primary_10_1002_mus_28356
crossref_primary_10_3390_cells8030237
crossref_primary_10_1002_jimd_12644
crossref_primary_10_1016_j_pmr_2012_06_001
crossref_primary_10_1152_japplphysiol_01051_2006
crossref_primary_10_1016_j_pediatrneurol_2014_06_023
crossref_primary_10_1097_CND_0b013e318033457d
crossref_primary_10_1177_0883073814537379
crossref_primary_10_1016_j_ncl_2007_11_010
crossref_primary_10_1097_CND_0b013e3181a7b35f
crossref_primary_10_1016_j_biopsych_2017_08_007
crossref_primary_10_1016_j_nmd_2007_10_007
crossref_primary_10_1152_ajpendo_00120_2017
crossref_primary_10_1371_journal_pone_0022294
crossref_primary_10_1016_j_ijcard_2013_05_062
crossref_primary_10_1177_0009922818821890
crossref_primary_10_1016_j_yfrne_2011_06_003
crossref_primary_10_1111_cge_13139
crossref_primary_10_3233_JND_140061
crossref_primary_10_3390_genes14050954
crossref_primary_10_1002_14651858_CD003907_pub4
crossref_primary_10_1016_j_hfc_2021_07_003
crossref_primary_10_1002_14651858_CD003907_pub5
crossref_primary_10_1093_brain_awn252
crossref_primary_10_3389_fphys_2019_00503
crossref_primary_10_1172_jci_insight_155201
crossref_primary_10_3390_jcm10081796
crossref_primary_10_1016_j_bbagen_2013_11_016
crossref_primary_10_1016_j_nmd_2013_05_007
crossref_primary_10_33549_physiolres_934529
crossref_primary_10_1016_j_mito_2011_05_005
crossref_primary_10_1152_ajpregu_00264_2016
crossref_primary_10_1093_brain_awr293
crossref_primary_10_1111_j_1365_2796_2008_02058_x
crossref_primary_10_1007_s12035_015_9090_9
crossref_primary_10_3389_fneur_2019_00790
crossref_primary_10_3389_fphys_2020_615038
crossref_primary_10_1016_j_nmd_2019_09_012
crossref_primary_10_4236_ijcm_2016_77054
crossref_primary_10_1152_ajpendo_00230_2011
crossref_primary_10_2174_0113892029308327240612110334
crossref_primary_10_3390_muscles3040033
crossref_primary_10_3389_fneur_2024_1499876
crossref_primary_10_1007_s10059_009_0071_6
crossref_primary_10_1042_EBC20170097
crossref_primary_10_1152_japplphysiol_91571_2008
crossref_primary_10_1016_j_arr_2016_04_006
crossref_primary_10_1016_j_cophys_2019_05_011
crossref_primary_10_1016_j_mito_2024_101979
crossref_primary_10_3390_jcm10010094
crossref_primary_10_1016_j_jrm_2011_09_010
crossref_primary_10_1007_s11825_012_0345_9
crossref_primary_10_3390_jcm7020016
crossref_primary_10_1097_WCO_0b013e32833d1096
crossref_primary_10_1016_j_arr_2023_101906
crossref_primary_10_1111_j_1468_1331_2009_02660_x
crossref_primary_10_1002_mus_21758
crossref_primary_10_1042_BCJ20220233
crossref_primary_10_3390_ijms22136913
crossref_primary_10_1016_j_nmd_2012_10_012
crossref_primary_10_1016_j_cell_2020_02_051
crossref_primary_10_3233_JND_150101
crossref_primary_10_1016_j_bbabio_2009_09_005
crossref_primary_10_3390_life11111111
crossref_primary_10_1007_s13311_018_00674_4
crossref_primary_10_1016_j_nmd_2012_10_005
crossref_primary_10_1016_j_pmr_2008_10_011
crossref_primary_10_1507_endocrj_EJ15_0479
crossref_primary_10_1152_japplphysiol_00885_2015
crossref_primary_10_5124_jkma_2024_67_9_560
crossref_primary_10_1111_j_1469_8749_2009_03605_x
crossref_primary_10_1007_s11010_020_04021_0
crossref_primary_10_1016_j_mito_2013_09_003
crossref_primary_10_1002_mus_26498
crossref_primary_10_1007_s00393_012_1082_9
crossref_primary_10_1016_j_tem_2012_04_006
crossref_primary_10_1093_brain_aws200
crossref_primary_10_1371_journal_pone_0041817
crossref_primary_10_1016_j_bbabio_2015_03_001
crossref_primary_10_1016_j_cmet_2015_05_006
crossref_primary_10_1007_s00415_021_10821_1
crossref_primary_10_1212_WNL_0000000000007265
crossref_primary_10_1016_j_nmd_2010_01_010
crossref_primary_10_1016_j_nmd_2013_08_004
crossref_primary_10_1212_WNL_0000000000005243
crossref_primary_10_1042_CS20160200
crossref_primary_10_1186_s13287_019_1510_8
crossref_primary_10_3389_fphys_2020_594223
crossref_primary_10_3390_cells12202494
crossref_primary_10_3389_fphys_2020_00349
crossref_primary_10_1002_mus_23771
crossref_primary_10_1016_j_heliyon_2024_e39648
crossref_primary_10_3390_ijms24055005
crossref_primary_10_1007_s40291_020_00510_6
crossref_primary_10_1093_brain_awx168
crossref_primary_10_1002_mus_23491
ContentType Journal Article
Copyright 2007 INIST-CNRS
Copyright Oxford University Press(England) Dec 2006
Copyright_xml – notice: 2007 INIST-CNRS
– notice: Copyright Oxford University Press(England) Dec 2006
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7QR
7TK
8FD
FR3
K9.
NAPCQ
P64
7TS
7X8
DOI 10.1093/brain/awl149
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Neurosciences Abstracts
Technology Research Database
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
Physical Education Index
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Nursing & Allied Health Premium
Technology Research Database
ProQuest Health & Medical Complete (Alumni)
Chemoreception Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Physical Education Index
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Nursing & Allied Health Premium

Neurosciences Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1460-2156
EndPage 3412
ExternalDocumentID 1175633151
16815877
18360636
10_1093_brain_awl149
ark_67375_HXZ_4ZV74L6Z_S
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-E4
-~X
.2P
.55
.GJ
.I3
.XZ
.ZR
0R~
1TH
23N
2WC
354
3O-
4.4
41~
482
48X
53G
5GY
5RE
5VS
5WA
5WD
6PF
70D
AABZA
AACZT
AAIMJ
AAJKP
AAJQQ
AAMDB
AAMVS
AAOGV
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
AAVLN
AAWTL
ABDFA
ABEJV
ABEUO
ABGNP
ABIVO
ABIXL
ABJNI
ABKDP
ABLJU
ABMNT
ABNGD
ABNHQ
ABNKS
ABPQP
ABPTD
ABQLI
ABQNK
ABVGC
ABWST
ABXVV
ABXZS
ABZBJ
ACBNA
ACGFS
ACIWK
ACPRK
ACUFI
ACUKT
ACUTO
ACYHN
ADBBV
ADEYI
ADEZT
ADGKP
ADGZP
ADHKW
ADHZD
ADIPN
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEJOX
AEKSI
AELWJ
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFZL
AFGWE
AFIYH
AFOFC
AFXAL
AGINJ
AGKEF
AGORE
AGQPQ
AGQXC
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AIJHB
AJBYB
AJEEA
AJNCP
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
ARIXL
ASPBG
ATGXG
AVWKF
AXUDD
AYOIW
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BQDIO
BR6
BSCLL
BSWAC
BTRTY
BVRKM
C1A
C45
CAG
CDBKE
COF
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBS
EE~
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HVGLF
HW0
HZ~
IOX
J21
J5H
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
MHKGH
ML0
N4W
N9A
NGC
NLBLG
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBOKY
OCZFY
ODMLO
OHH
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
ROL
ROX
ROZ
RUSNO
RW1
RXO
RZO
TCURE
TEORI
TJX
TLC
TR2
VVN
W8F
WH7
WOQ
X7H
X7M
XJT
XOL
YAYTL
YKOAZ
YSK
YXANX
ZCG
ZKX
~91
AAYXX
CITATION
RIG
1CY
AAGKA
AAPGJ
AAQQT
AAWDT
AAYJJ
ABDPE
ABIME
ABPIB
ABSMQ
ABZEO
ACFRR
ACPQN
ACUTJ
ACVCV
ACZBC
ADMTO
AEHUL
AEKPW
AFFQV
AFSHK
AFYAG
AGKRT
AGMDO
AHGBF
AI.
AJDVS
ANFBD
APJGH
AQDSO
AQKUS
ASAOO
ATDFG
ATTQO
AVNTJ
BZKNY
CXTWN
DFGAJ
EIHJH
ELUNK
IQODW
MBLQV
MBTAY
MVM
OBFPC
OHT
O~Y
QBD
RNI
RZF
TCN
TMA
VH1
YQJ
ZGI
ZKB
ZXP
6.Y
ABQTQ
ABSAR
ADJQC
ADRIX
AFXEN
CGR
CUY
CVF
ECM
EIF
M49
NPM
VXZ
7QP
7QR
7TK
8FD
FR3
K9.
NAPCQ
P64
7TS
7X8
ID FETCH-LOGICAL-c447t-a181e5ce72c6b52de84697635a5c789f14b04eae7f3d034e9668041a30a9f6e13
ISSN 0006-8950
1460-2156
IngestDate Sat Sep 27 18:36:31 EDT 2025
Fri Sep 05 08:07:44 EDT 2025
Sun Sep 28 12:05:22 EDT 2025
Sun Jun 29 16:45:10 EDT 2025
Wed Feb 19 01:46:40 EST 2025
Mon Jul 21 09:13:16 EDT 2025
Thu Apr 24 22:53:26 EDT 2025
Tue Jul 01 02:39:58 EDT 2025
Sat Sep 20 11:00:29 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords Physical exercise
Human
Nervous system diseases
mtDNA
Metabolic diseases
training
Enzymopathy
Congenital disease
Striated muscle disease
Mitochondria
mutation load
Mitochondrial myopathy
Mutation
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c447t-a181e5ce72c6b52de84697635a5c789f14b04eae7f3d034e9668041a30a9f6e13
Notes istex:FB357A596C7B4D2DD31BC7E132C2502EBB6DC28D
ark:/67375/HXZ-4ZV74L6Z-S
Abbreviations CKcreatine kinase HRheart rate MMmitochondrial myopathy mtDNAmitochondrial DNA RRFragged red fibres VO2maxmaximal oxygen uptake Wmaxmaximal workload
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
PMID 16815877
PQID 195430233
PQPubID 35133
PageCount 11
ParticipantIDs proquest_miscellaneous_771744824
proquest_miscellaneous_68197598
proquest_miscellaneous_19498543
proquest_journals_195430233
pubmed_primary_16815877
pascalfrancis_primary_18360636
crossref_primary_10_1093_brain_awl149
crossref_citationtrail_10_1093_brain_awl149
istex_primary_ark_67375_HXZ_4ZV74L6Z_S
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2006-12-01
PublicationDateYYYYMMDD 2006-12-01
PublicationDate_xml – month: 12
  year: 2006
  text: 2006-12-01
  day: 01
PublicationDecade 2000
PublicationPlace Oxford
PublicationPlace_xml – name: Oxford
– name: England
PublicationTitle Brain (London, England : 1878)
PublicationTitleAlternate Brain
PublicationYear 2006
Publisher Oxford University Press
Oxford Publishing Limited (England)
Publisher_xml – name: Oxford University Press
– name: Oxford Publishing Limited (England)
SSID ssj0014326
Score 2.2911167
Snippet Exercise intolerance is a prominent symptom in patients with mitochondrial myopathy (MM), but it is still unsettled whether exercise training is safe and...
SourceID proquest
pubmed
pascalfrancis
crossref
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 3402
SubjectTerms Adult
Aerobiosis - physiology
Biological and medical sciences
Creatine Kinase - blood
Diseases of striated muscles. Neuromuscular diseases
DNA, Mitochondrial - genetics
Exercise Therapy - methods
Female
Gene Deletion
Heart Rate - physiology
Humans
Lactates - blood
Male
Medical sciences
Middle Aged
Mitochondria - enzymology
Mitochondrial Myopathies - genetics
Mitochondrial Myopathies - physiopathology
Mitochondrial Myopathies - therapy
mitochondrial myopathy
mtDNA
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
Muscle, Skeletal - enzymology
Muscle, Skeletal - pathology
Muscle, Skeletal - physiopathology
mutation load
Neurology
Oxygen Consumption - physiology
Point Mutation - genetics
Quality of Life
training
Treatment Outcome
Title Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy
URI https://api.istex.fr/ark:/67375/HXZ-4ZV74L6Z-S/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/16815877
https://www.proquest.com/docview/195430233
https://www.proquest.com/docview/19498543
https://www.proquest.com/docview/68197598
https://www.proquest.com/docview/771744824
Volume 129
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1460-2156
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0014326
  issn: 0006-8950
  databaseCode: KQ8
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1460-2156
  dateEnd: 20240930
  omitProxy: true
  ssIdentifier: ssj0014326
  issn: 0006-8950
  databaseCode: DIK
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1460-2156
  dateEnd: 20240930
  omitProxy: true
  ssIdentifier: ssj0014326
  issn: 0006-8950
  databaseCode: GX1
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKJiFeEN8Lg-EH4KVKlw_HTh4HpSqDwQMdVH2JnMQRE11a9UMD_hD-Xu5iJ2mmVhq8RJV7TuLcz-e78_mOkJeggqe-k4U2T13PZsIJ7ETIzM5llLhZ6uHpT4y2-MSH5-x0HIw7nT8bUUvrVdJLf289V_I_XIU24Cuekv0HztY3hQb4DfyFK3AYrjfi8YnCLEppXecBq5MvZW52BEp3gVrWVZW6KSyMKWrdTT5Vc7jtEuY1yMEiK2t4XP6aYaHi9oYvPmJr_Q_tVAhFuOFUOFXzuTK-nVGv2-81-z3fr2Agpdf6rG79PDW0_V73Td36DS157fce9K55J5pIj0ricjuMdHLZntJClnHHBlWDt6SweUcDN29DqPrM8TYWaFh3va3CXyfGShalS2Ugr6auzobazrJ9bfWrYxL1brwfl_1j3fsW2fcE51gZo__-Q707xfyyjF89NnOgAnofl72Pde-WqrOPs_Ynht7KJcy-XJdN2W3XlPrN6B65awwTeqJRdp90VPGA3D4zoRcPSWzARiuw0YslRbBR4BGtwEYrsNEKbPSioBXYKIKNtsBGK7A9IueDd6O3Q9tU57BTxsTKlqAbqiBVwkt5EniZAk02wvSGMkhFGOUuSxympBK5nzk-U2BXY64r6Tsyyrly_cdkr5gV6oDQQPgciTwHjJFEgY2bR0mU5F6Qg36eKYt0qw8ZpyZ1PQ52Gm9jmkVe1dRznbJlB93rkic1kVz8wDBHEcTD8SRmk6-CfeST-ItFjlpMa-6KJ6C4zy1yWHExNuJhGWMqRazI5VvkRf0vyG7ckJOFmq2RhEUhUO2m4KCwiyAKLUJ3UAjhCsZCj1nkicZP83rQOwiFeHrDD3JI7jRT-BnZWy3W6jmo3KvkqMT_X31E2FM
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Aerobic+training+is+safe+and+improves+exercise+capacity+in+patients+with+mitochondrial+myopathy&rft.jtitle=Brain+%28London%2C+England+%3A+1878%29&rft.au=Jeppesen%2C+T.+D.&rft.au=Schwartz%2C+M.&rft.au=Olsen%2C+D.+B.&rft.au=Wibrand%2C+F.&rft.date=2006-12-01&rft.issn=0006-8950&rft.eissn=1460-2156&rft.volume=129&rft.issue=12&rft.spage=3402&rft.epage=3412&rft_id=info:doi/10.1093%2Fbrain%2Fawl149&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_brain_awl149
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-8950&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-8950&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-8950&client=summon